Recce Pharmaceuticals' R327G Shows Promising Results in Phase II Trial for Skin Infections
RCE (RCE) Share Update November 2024 Monday 4th
Recce Pharmaceuticals Nears Completion of Promising Phase II Trial for R327G
Recce Pharmaceuticals Limited (ASX:RCE, FSE:R9Q) has announced significant progress in its Phase II clinical trial for RECCE® 327 Topical Gel (R327G), targeting Acute Bacterial Skin and Skin Structure Infections (ABSSSI).
Instant Summary:
- Phase II trial for R327G reaches dosing milestone with 20 out of 30 patients dosed.
- All dosed patients met primary endpoints, showing either cure or notable improvement.
- No Serious Adverse Events (SAEs) reported for R327G.
- Trial completion expected within CY24.
Phase II Trial Progress
Recce Pharmaceuticals is nearing the completion of its Phase II clinical trial for RECCE® 327 Topical Gel (R327G), a treatment for Acute Bacterial Skin and Skin Structure Infections (ABSSSI). With 20 out of 30 patients dosed, the interim results are promising, demonstrating a strong therapeutic response. All patients treated with R327G have shown either a complete cure or notable improvement, with no serious adverse events reported.
Dr. Alan W Dunton, Chief Medical Advisor of Recce Pharmaceuticals, highlighted the significance of these results, stating that they represent a remarkable advancement in addressing unmet medical needs in anti-infective therapies. The robust response observed in the trial is encouraging as the company moves closer to completing the Phase II trial by the end of 2024.
Market Potential and Future Steps
The market for ABSSSI is projected to reach USD26 billion by 2032, presenting a substantial opportunity for Recce Pharmaceuticals. The successful completion of this trial could pave the way for further regulatory evaluation and potential market entry. The company's focus remains on delivering a pioneering synthetic anti-infective topical therapy to address these complex bacterial infections.
Recce Pharmaceuticals is committed to advancing R327G through the clinical trial process, supported by the non-DSMB's unanimous endorsement, which reflects the positive trajectory of the drug's development. This progress supports the continued advancement of R327G towards regulatory approval.
The positive interim results from the Phase II trial of R327G are likely to boost investor confidence in Recce Pharmaceuticals. The absence of serious adverse events and the achievement of primary endpoints suggest a strong safety and efficacy profile, which could enhance the company's position in the anti-infective market. As the trial nears completion, the potential for R327G to address a significant market need could positively influence the company's stock price.
Investor Reaction:
Analysts are expected to react positively to the interim results, noting the strong therapeutic response and lack of serious adverse events as key indicators of R327G's potential. The significant market opportunity for ABSSSI treatments may further bolster investor interest in Recce Pharmaceuticals.
Conclusion:
Investors should keep a close eye on the completion of the Phase II trial and subsequent regulatory developments. The promising results for R327G could position Recce Pharmaceuticals as a leader in the synthetic anti-infective market, offering potential growth opportunities for investors.